Sacubitril/valsartan eligibility and outcomes in the ESC HFA EORP Heart Failure Long-Term Registry: bridging between EMA/FDA label, the PARADIGM-HF trial, ESC Guidelines, and real-world

European Journal of Heart Failure

30 Maggio Mag 2019 4 months ago
  • Agostoni P, Italiano G, Salvioni E tra i collaboratori

To assess the proportion of patients with heart failure and reduced ejection fraction (HFrEF) who are eligible for LCZ696 based on EMA/FDA label, the PARADIGM-HF trial and ESC-Heart Failure Association (ESC-HFA) Guidelines, and the association between eligibility and outcomes.

Reference

Kapelios CJ, Lainscak M, Savarese G, Laroche C, Seferovic P, Ruschitzka F, Coats A, Anker SD, Crespo-Leiro MG, Filippatos G, Piepoli MF, Rosano G, Zanolla L, Aguiar C, Murin J, Leszek P, McDonagh T, Maggioni AP, Lund LH; HF LT Registry Investigators group. Sacubitril/valsartan eligibility and outcomes in the ESC HFA EORP Heart Failure Long-Term Registry: bridging between EMA/FDA label, the PARADIGM-HF trial, ESC Guidelines, and real-world. Eur J Heart Fail 2019 May 27. doi: 10.1002/ejhf.1532.

Go to PubMed